title: Extracorporeal photochemotherapy in systemic sclerosis and severe morphea.
abstract: BACKGROUND
  Extracorporeal photochemotherapy (EP) is a new immune-modulating therapy which combines cytapheresis and extracorporeal irradiation of leukocytes by UVA. Recently, patients with systemic sclerosis (SS) have been treated by this method, but the efficacy of EP is still controversial.
  
  
  OBJECTIVE
  Our purpose was to evaluate the efficacy and safety of EP in SS and in severe morphea.
  
  
  METHODS
  In an open study, 7 patients with SS and 2 patients with severe morphea were treated by EP and were evaluated after 6 months of treatment. No other treatments were allowed during this period.
  
  
  RESULTS
  Except one vasovagal reaction, EP was well tolerated in all patients. The surface of the cutaneous sclerosis was unchanged in 3 of the 7 patients with SS, whereas it was aggravated in the remaining 4 patients. There was no improvement of the visceral involvement of SS in these patients. Although the duration of SS was less than 4 years in 6 out of 7 patients, we did not observe any significant benefit from EP in SS patients. One patient with generalized morphea had stopped EP after 3 months because of loss of vascular access and could not be evaluated. In the last patient with linear morphea of the upper limbs, a reduction in the number of morphea plaques was observed, and the remaining lesions were less visible after 16 months of EP.
  
  
  CONCLUSIONS
  The present results do not corroborate those previously published with regard to the efficiency of EP in SS of recent onset. The efficacy of ECP in morphea needs further confirmation.
authors.affiliation: Clinique Dermatologique, Hôpitaux Universitaires, Strasbourg, France.
authors.forename: B
authors.initials: B
authors.lastname: Cribier
authors.forename: T
authors.initials: T
authors.lastname: Faradji
authors.forename: C
authors.initials: C
authors.lastname: Le Coz
authors.forename: F
authors.initials: F
authors.lastname: Oberling
authors.forename: E
authors.initials: E
authors.lastname: Grosshans
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001168:Arthritis / Q000188:drug therapy / Q000473:pathology; D018450:Disease Progression; D004361:Drug Tolerance; D004935:Esophageal Diseases / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008730:Methoxsalen / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D008875:Middle Aged; D017893:Photopheresis / Q000009:adverse effects; D012449:Safety; D012594:Scleroderma, Localized / Q000188:drug therapy* / Q000473:pathology; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000473:pathology; D014630:Vagus Nerve / Q000187:drug effects; D014666:Vasomotor System / Q000187:drug effects
chemical_list: D008730:Methoxsalen